Cargando…
L’Health Technology Assessment come strumento value-based per la valutazione delle tecnologie sanitarie. Reassessment del vaccino antinfluenzale quadrivalente da coltura cellulare: Flucelvax Tetra(®) 2.0
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Pacini Editore srl
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079375/ https://www.ncbi.nlm.nih.gov/pubmed/37034835 http://dx.doi.org/10.15167/2421-4248/jpmh2022.63.4s1 |
| _version_ | 1785020715386273792 |
|---|---|
| author | CALABRÒ, GIOVANNA ELISA BOCCALINI, SARA BECHINI, ANGELA PANATTO, DONATELLA DOMNICH, ALEXANDER LAI, PIERO LUIGI AMICIZIA, DANIELA RIZZO, CATERINA PUGLIESE, ANDREA DI PIETRO, MARIA LUISA ZANELLA, BEATRICE PARENTE, FLAVIO TROMBETTA, CARLO SIMONE SARACENO, GIOVANNI SOTTILE, SARA ABREHA, FASIKA MOLLA GIACCHETTA, IRENE PROPERZI, SARA SANTOLINI, GIULIA D’AMBROSIO, FLORIANA MAIDA, ADA SCARDIGNO, ANNA LA GATTA, EMANUELE PETRELLA, LUIGI BONANNI, PAOLO DE WAURE, CHIARA |
| author_facet | CALABRÒ, GIOVANNA ELISA BOCCALINI, SARA BECHINI, ANGELA PANATTO, DONATELLA DOMNICH, ALEXANDER LAI, PIERO LUIGI AMICIZIA, DANIELA RIZZO, CATERINA PUGLIESE, ANDREA DI PIETRO, MARIA LUISA ZANELLA, BEATRICE PARENTE, FLAVIO TROMBETTA, CARLO SIMONE SARACENO, GIOVANNI SOTTILE, SARA ABREHA, FASIKA MOLLA GIACCHETTA, IRENE PROPERZI, SARA SANTOLINI, GIULIA D’AMBROSIO, FLORIANA MAIDA, ADA SCARDIGNO, ANNA LA GATTA, EMANUELE PETRELLA, LUIGI BONANNI, PAOLO DE WAURE, CHIARA |
| author_sort | CALABRÒ, GIOVANNA ELISA |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10079375 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Pacini Editore srl |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100793752023-04-07 L’Health Technology Assessment come strumento value-based per la valutazione delle tecnologie sanitarie. Reassessment del vaccino antinfluenzale quadrivalente da coltura cellulare: Flucelvax Tetra(®) 2.0 CALABRÒ, GIOVANNA ELISA BOCCALINI, SARA BECHINI, ANGELA PANATTO, DONATELLA DOMNICH, ALEXANDER LAI, PIERO LUIGI AMICIZIA, DANIELA RIZZO, CATERINA PUGLIESE, ANDREA DI PIETRO, MARIA LUISA ZANELLA, BEATRICE PARENTE, FLAVIO TROMBETTA, CARLO SIMONE SARACENO, GIOVANNI SOTTILE, SARA ABREHA, FASIKA MOLLA GIACCHETTA, IRENE PROPERZI, SARA SANTOLINI, GIULIA D’AMBROSIO, FLORIANA MAIDA, ADA SCARDIGNO, ANNA LA GATTA, EMANUELE PETRELLA, LUIGI BONANNI, PAOLO DE WAURE, CHIARA J Prev Med Hyg Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra® 2.0 Pacini Editore srl 2023-03-02 /pmc/articles/PMC10079375/ /pubmed/37034835 http://dx.doi.org/10.15167/2421-4248/jpmh2022.63.4s1 Text en ©2023 Pacini Editore SRL, Pisa, Italy https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en |
| spellingShingle | Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra® 2.0 CALABRÒ, GIOVANNA ELISA BOCCALINI, SARA BECHINI, ANGELA PANATTO, DONATELLA DOMNICH, ALEXANDER LAI, PIERO LUIGI AMICIZIA, DANIELA RIZZO, CATERINA PUGLIESE, ANDREA DI PIETRO, MARIA LUISA ZANELLA, BEATRICE PARENTE, FLAVIO TROMBETTA, CARLO SIMONE SARACENO, GIOVANNI SOTTILE, SARA ABREHA, FASIKA MOLLA GIACCHETTA, IRENE PROPERZI, SARA SANTOLINI, GIULIA D’AMBROSIO, FLORIANA MAIDA, ADA SCARDIGNO, ANNA LA GATTA, EMANUELE PETRELLA, LUIGI BONANNI, PAOLO DE WAURE, CHIARA L’Health Technology Assessment come strumento value-based per la valutazione delle tecnologie sanitarie. Reassessment del vaccino antinfluenzale quadrivalente da coltura cellulare: Flucelvax Tetra(®) 2.0 |
| title | L’Health Technology Assessment come strumento
value-based per la valutazione delle tecnologie sanitarie.
Reassessment del vaccino antinfluenzale quadrivalente da
coltura cellulare: Flucelvax Tetra(®) 2.0 |
| title_full | L’Health Technology Assessment come strumento
value-based per la valutazione delle tecnologie sanitarie.
Reassessment del vaccino antinfluenzale quadrivalente da
coltura cellulare: Flucelvax Tetra(®) 2.0 |
| title_fullStr | L’Health Technology Assessment come strumento
value-based per la valutazione delle tecnologie sanitarie.
Reassessment del vaccino antinfluenzale quadrivalente da
coltura cellulare: Flucelvax Tetra(®) 2.0 |
| title_full_unstemmed | L’Health Technology Assessment come strumento
value-based per la valutazione delle tecnologie sanitarie.
Reassessment del vaccino antinfluenzale quadrivalente da
coltura cellulare: Flucelvax Tetra(®) 2.0 |
| title_short | L’Health Technology Assessment come strumento
value-based per la valutazione delle tecnologie sanitarie.
Reassessment del vaccino antinfluenzale quadrivalente da
coltura cellulare: Flucelvax Tetra(®) 2.0 |
| title_sort | l’health technology assessment come strumento
value-based per la valutazione delle tecnologie sanitarie.
reassessment del vaccino antinfluenzale quadrivalente da
coltura cellulare: flucelvax tetra(®) 2.0 |
| topic | Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra® 2.0 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079375/ https://www.ncbi.nlm.nih.gov/pubmed/37034835 http://dx.doi.org/10.15167/2421-4248/jpmh2022.63.4s1 |
| work_keys_str_mv | AT calabrogiovannaelisa lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT boccalinisara lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT bechiniangela lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT panattodonatella lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT domnichalexander lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT laipieroluigi lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT amiciziadaniela lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT rizzocaterina lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT puglieseandrea lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT dipietromarialuisa lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT zanellabeatrice lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT parenteflavio lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT trombettacarlosimone lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT saracenogiovanni lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT sottilesara lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT abrehafasikamolla lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT giacchettairene lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT properzisara lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT santolinigiulia lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT dambrosiofloriana lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT maidaada lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT scardignoanna lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT lagattaemanuele lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT petrellaluigi lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT bonannipaolo lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 AT dewaurechiara lhealthtechnologyassessmentcomestrumentovaluebasedperlavalutazionedelletecnologiesanitariereassessmentdelvaccinoantinfluenzalequadrivalentedacolturacellulareflucelvaxtetra20 |